anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Laboratory instruments may be interfaced into an existing laboratory subsystem. The subsystem may be obtained including a first instrument, a transport assembly, and a controller configured to communicate with the first instrument and the transport assembly using a first data format. A second instrument may be attached to the subsystem using an adapter device to form a completed sample processing system. The second instrument may communicate using a second data format. The completed sample processing system may include a translation module configured to convert data from the second data format to the first data format. The completed sample processing system may be used to process biological or chemical samples using the transport assembly, the first instrument, and the second instrument. The translation module may convert the data communicated from the second instrument to the subsystem by converting the data from the second data format to the first data format.
Postmenopausal women receive an aromatase inhibitor together with palbociclib 125 mg orally days 1-21, followed by a 7-days rest period, repeated twice during a 12-week period. Thereafter, treatment is switched to weekly paclitaxel 80mg/m2, eventually dose-adjusted in relation to side effects, for further 12 weeks.
Study interventions include a medical history and short physical examination as well as autonomic function tests and cerebral autoregulation tests on the day before surgery. In addition we determine CO2 sensitivity of the cerebral vasculature by three minutes hyperventilation and three minutes CO2 rebreathing. Perioperatively, continuous measurement of heart rate, blood pressure, stroke volume and cardiac output is aquired using the ccNexfin monitor, a non-invasive device using a single finger cuff. Continuous monitoring of cerebral perfusion parameters using transcranial Doppler ultrasound (TCD) of the middle cerebral artery (MCA) and cerebral oxygenation using near-infrared-spectroscopy (NIRS) will be obtained. BRS and condition of CA will be determined preoperatively during autonomic function testing (see below) and 30 minutes after induction of anaesthesia.
A purified, detoxified endotoxin contg. no detactable 2-keto3- deoxyoctanoate, 350-475 nM/mg P and 1700-2000 nM/mg fatty acids was prepd. and it can be used as a B-cell mitogen and as an immune adjuvant.  Thus, endotoxin was extd. from bacteria by MeOH-CHCl3 pptn. and the crude lipid A ext. was detoxified by dissolving it in acetone.  The detoxified endotoxin was then purified on Sephadex, DEAE-C=ellulose, or a silica gel. column.  This purified, detoxified endotoxin enhanced the immune response of BALB/c mice to SRBC as compared with SRBC alone or SRBC and standard endotoxin.
This study explored the effects of fructose-induced obesity and metabolic disorders on peripheral inflammatory hyperalgesia, employing quantitative sensory testing with the von Frey test and measuring paw edema to assess inflammatory responses. Wistar rats were administered water or 10% fructose solution ad libitum over a period of 5 weeks. After intraplantar administration of inflammatory agents such as carrageenan (1 mg/paw), lipopolysaccharide (LPS; 100 µg/paw), or prostaglandin E2 (PGE2, 100 ng/paw), we conducted mechanical hyperalgesia tests and paw edema evaluations. The fructose diet resulted in dyslipidemia, elevated insulin and leptin plasma levels, insulin resistance, and increased epididymal and retroperitoneal adiposity compared to control animals. In response to inflammatory agents, the fructose group displayed significantly enhanced peripheral hyperalgesia and more pronounced paw edema. Our results demonstrate that fructose not only contributes to the development of obesity and metabolic disorder but also exacerbates peripheral inflammatory pain responses by enhancing prostaglandin sensitivity.
Subjects meeting inclusion criteria, including sleep study and drug induced sleep endoscopy criteria, will undergo surgical placement of a hypoglossal nerve simulator (Inspire® Upper Airway Simulation System Model 3028 IPG). The simulator will be activated one month after surgery and subjects will undergo repeat sleep study evaluation and device titration at one, two, six and twelve months after implantation. Subjects will be followed for one year to determine safety and efficacy of the device.
L-Dopa (3,4-dihydroxy-L-phenylalanine), which is used in the therapy of Parkinsonism, is isolated from plant extract on active charcoal, (b) eluting L-dopa with a suitable eluant; (c) repeatedly pouring the eluant onto an ion-exchange resin column which retains L-dopa; (d) eluting L-dopa from the column with ammonia soln; (e) neutralising the resulting soln so to crystalline L-dopa, and (f) opt. recrystallising the L-dopa thus obtd. The process avoids the use of Pb salts. Non-toxic mother liquors are obtd. which can be used as a fertiliser. Distn. is avoided and inflammable solvents and H2S are not used. Process is suitable for continuous operations.
Expansion cohorts of monotherapy DF1001 in multiple dose levels after evaluation for safety in Monotherapy Dose Escalation arm. Additional pharmacokinetic (PK) and pharmacodynamic (PD) samples included in this arm.
The present invention relates to a natural extract composition effective for oxidative damage and inflammation. More particularly, the present invention relates to a composition effective for oxidative damage and inflammation, which comprises Cnidium officinale MAKINO, Schizonepeta tenuifolia var. japonica, licorice, Ledebouriella seseloides WOLFF., or the like, and a pharmaceutical composition comprising the same. In addition, the present invention provides a composition effective for oxidative damage and inflammation, which is obtained by mixing and extracting Cnidium officinale MAKINO, Schizonepeta tenuifolia var. japonica, licorice, Ledebouriella seseloides WOLFF., Angelica dahurica root, Betulae Cortex, Magnolia denudata Desrousseaux, peppermint and Hepatica asiatica. In addition, the present invention provides a composition effective for oxidative damage and inflammation, which is obtained by mixing and extracting 100 parts by weight of Cnidium officinale MAKINO, 80-120 parts by weight of Schizonepeta tenuifolia var. japonica, 40-60 parts by weight of licorice, 40-60 parts by weight of Ledebouriella seseloides WOLFF., 40-60 parts by weight of Angelica dahurica root, 40-60 parts by weight of Betulae Cortex, 25-40 parts by weight of Magnolia denudata Desrousseaux, 20-30 parts by weight of peppermint and 20-30 parts by weight of Hepatica asiatica. The present invention also provides a pharmaceutical composition comprising the composition effective for oxidative damage and inflammation.
The invention provides an application of mango extracts to preparation of drugs or health care products for controlling tumor diseases. The mango extracts are crude pure powder obtained by extracting mango peels or kernels with 80% of acetone and carrying out primary purification on the extracts through C18 solid phase extraction. The main ingredients of the mango extracts include fivefold gallotannin and derivatives thereof. The drugs or the health care products are prepared from the mango extracts and preparation allowable excipients or food additives. Researches prove that the mango extracts have the activity of inhibiting breast cancers, liver cancers and leukemia and can be used for preparing the drugs for treating breast cancers, liver cancers and leukemia and inhibiting cell activities of breast cancers, liver cancers and leukemia or can be developed into functional food or health care products. The invention provides a new application of mango processing byproducts, namely the mango peel and kernel extracts to tumor treatment drugs or health care products.
Participation in this research study involves two research visits, at least one of which is at Children's Hospital Boston. The first visit lasts about 4-6 hours. On this visit, the child will work with a research assistant on a few different cognitive assessments while one or both parents answer interview questionnaires about the child's development, along with other family history information. The second visit at the hospital lasts about 2 and a half hours and involves medical history and family history questionnaires, as well as height, weight, and head circumference measurements and a blood draw from each family member. In addition, digital photographs will be taken of each family member and a 3-D picture of the child's face will be taken. Shortly after the visits, participants will receive a research report of our observations. These results include cognitive, behavioral, developmental, and social findings. The total time commitment for the study is 6 to 8 hours.
Patients with T1DM were randomly assigned in a 1:1 ratio to receive 3 SC injections of either dasiglucagon (0.6 mg) or GlucaGen (1 mg), with 1 week between doses. Patients were followed for 15 weeks from the day of the first dose to assess the immune response. Patients with previous exogenic glucagon exposure were not excluded from the trial, but the information on previous glucagon administration was recorded to enable subgroup analyses. It was expected that 112 patients in total would be randomly assigned to treatment groups and treated. A total of 90 patients were expected to complete the trial (45 in each treatment arm). To qualify as completed, the patient had to be dosed according to the procedure described in the protocol and to have blood drawn for the antidrug antibody analyses as scheduled.
Motor imagery is a technique for inducing motor activity in response to a certain motor output by producing a mental image of the action without intending to conduct it. It is a cognitive technique that, rather than making a patient to pick up new procedures, promotes neural alterations in order enable the patient to re-acquire motor skills mastered before the CVA or copy the actions of others. Motor imaging training is a sort of therapy in which the patient imagines a gesture or movement in order to learn, reinforce, or improve the movement's performance. A study done in South Korea, published in 2015, revealed that Motor imagery training has a good impact on UL performance by refining functional mobility during stroke rehabilitation. The results suggest that motor imagery training is viable and helpful for improving UL function in CVA patients.

Meta-analysis done in Australia in the year 2013, was supportive of Motor imaginary techniques further convincing that Mental imagery can be a possible intervention for stroke patients given that it being, safe cost-effective \& unlimited practice opportunities. Study done in China in 2017, suggested that clinicians should consider the use of MI in addition to treatment currently used to improve upper extremity functions after stroke as no evidence of side effects or harm was noted . RCT done in year 2006 in USA indicated that for patients with chronic, moderate upper limb impairment after CVA, program of CIMT with mental practice only resulted in decrease impairment, with functional enhancement.
The SIM03 (supplied by GenieBiome Limited and produced under Good Manufacturing Practice, GMP) contains a blend of naturally occurring food-grade Bifidobacterium strains (1 billion CFU in 1 sachet). Recruited subjects will receive one sachet of baby immunity formula SIM03 twice daily for 3 months.
The present invention provides various pharmaceutical compositions compri sing an S1P receptor modulator, e.g. an S1P receptor agonist. In one aspect, there is provided a pharmaceutical composition having a coating. In other a spects, rapid disintegrating compositions are provided. In a further aspect, a pharmaceutical composition which is free of sugar alcohols is provided. I n another aspect, the invention provides a pharmaceutical composition compri sing a coating comprising an S1P receptor modulator.
AIMS: This prospective study aimed to evaluate the characteristics and findings of children who presented with acute pyelonephritis (APN) and to determine the independent risk factors for kidney scarring.
MATERIAL AND METHODS: Patients who satisfied the following criteria were enrolled in the study: first known episode of APN; at least two of the following findings: fever ≥ 38.5 °C, white blood cell count ≥ 10,000/mm3, erythrocyte sedimentation rate ≥ 20 mm/h, C-reactive protein ≥ 20 mg/dL; absence of congenital abnormalities or other kidney and systemic diseases, except vesicoureteral reflux (VUR); no APN relapses until the time of kidney scar detection. 99mTc-Dimercaptosuccinic acid kidney scintigraphy (99mTc-DMSA) was performed at admission, along with a kidney ultrasound. Follow-up 99mTc-DMSA took place after 6 months. Radiographic cystourethrography for VUR detection and grading was performed 1 month after the acute infection.
RESULTS: We enrolled 70 children in the study. The kidney ultrasound failed to diagnose more than half of the cases of APN. VUR was found in 21.5% of children. 75% had findings of APN in the acute phase through 99mTc-DMSA, while in the second 99mTc-DMSA, there was a complete remission in 68% of them. Scars were observed more frequently in older children, children with VUR grade ≥ III, and children not on antibiotic prophylaxis.
CONCLUSION: VUR did not appear to be associated with the first episode of APN, and children older than 1 year of age had a higher risk of scarring. Antibiotic prophylaxis may prevent kidney scarring due to host immunomodulatory effects, but more studies are needed so that conclusions can be drawn.
The invention discloses an application of gamma-mangostin in preventing and treating plant fungal diseases and human fungal diseases. In the screening of the activity of the rice blast resistant filter paper sheet plate, the inhibition rate of gamma-mangostin to rice blast is 51.40%, and the activity of the gamma-mangostin is far higher than that of alpha-mangostin, berberine, hesperetin, eugenol and physcion. Drug plate method for measuring gamma-mangostin against Pyricularia oryzae EC  50  293.55 μm, lower than the EC of berberine and kasugamycin  50  . In addition, the gamma-mangostin has inhibitory activity on various plant pathogenic fungi and can relieve the disease condition of pepper anthracnose. Meanwhile, detection shows that gamma-mangostin is effective on candida albicans, cryptococcus neoformans and cigarettesAspergillus has strong inhibitory activity and MIC of 3.9-62.5. Mu.M. In view of the high fungus inhibition activity and green safety characteristics of gamma-mangostin, the gamma-mangostin can be used for green prevention and control of plant fungus diseases and prevention and control of human pathogenic fungi.
This present disclosure is related to the field of 1-(substituted-benzoyl)-5-fluoro-4-imino-3-methyl-3,4-dihydropy rimidin-2(1H)-ones and their derivatives and to the use of these compounds as fungicides. Fungicides are compounds, of natural or synthetic origin, which act to protect and/or cure plants against damage caused by agriculturally relevant fungi. Generally, no single fungicide is useful in all situations. Consequently, research is ongoing to produce fungicides that may have better performance, are easier to use, and cost less. The present disclosure relates to 1-(substituted-benzoyl)-5-fluoro-4-imino-3-methyl-3,4-dihydropy rimidin-2(1 H)-one compounds and their use as fungicides. The compounds of the present disclosure may offer protection against fungi and fungi like organisms including ascomycetes, basidiomycetes, deuteromycetes, and oomycetes.
PURPOSE:To obtain an antitumor agent, containing an organoplatinum complex as an active ingredient, having a wide range of antitumor action and capable of exhibiting excellent propagation inhibitory effects especially on solid tumor. CONSTITUTION:The objective substance obtained by containing a novel organoplatinum complex expressed by formula I (R<1> is H or lower alkyl; R<2> is lower alkyl, lower alkenyl, lower alkanoyl, etc.; X is carbonyl or sulfonyl; m is 1 or 2), mixing the above-mentioned complex with normally used additives and preparing a formulation according to a conventional method. The afore- mentioned agent can be prepared in the form of tablet, granule, capsule, suppository, injection, etc. The dose of the compound expressed by formula I is 20-1000mg/m<2> per day. The compound expressed by formula I is capable of exhibiting high water solubility and hardly showing any nephrotoxicity. The compound expressed by formula I is obtained by reacting a 2(substituted amino) malonic acid expressed by formula II or a salt thereof with a 1,2- diaminocyclohexane complex expressed by formula III (X<1> and X<2> are reactive residue) at ambient temperature by a conventional method.
Accurate blood pressure (BP) measurement is required to provide appropriate healthcare. Inaccurate BPs may lead to under and/or over-treatment of health conditions and medical diseases such as hypertension. Blood pressure (BP) measurement using automatic, non-invasive oscillometric monitors is common in clinics, physicians'offices and hospital settings. The brachial (upper arm) site is the gold standard for non-invasive BPs. However, in some situations, this site is inaccessible due to injury, surgery, dialysis shunts, intravenous devices, and lymphedema. When the upper arm is difficult to access or the available BP cuffs do not fit an individual's arm, the forearm site is often the preferable alternative. The increased incidence of obesity nationally also contributes to the heightened use of forearm BPs. Questions remain concerning the accuracy of forearm non-invasive BP measurements. Although most researchers report that upper arm and forearm readings are not interchangeable, size of differences vary for individuals and factors influencing differences in readings have not been thoroughly investigated.
This study seeks to develop and test a fully online, self-administered psychoeducation program to enhance the caregiving mastery of family and friends who provide unpaid care for persons living with Alzheimer's and similar dementia disorders (PLWD). As the number of PLWD rises in the United States from the perhaps 7 million today to possibly 15 million in 2050, the healthcare system will rely on those caregivers even more. It is well established that family caregiving is taxing and stressful and that managing the day-to-day life of PLWD and handling the behavioral and psychological symptoms in dementia (BPSD) that they may exhibit are the main sources of stress. Group-based psychoeducational programs such as the Savvy Caregiver program (SCP) have demonstrated that the acquisition of skills, knowledge, and caregiving mastery can ameliorate caregiving stress - and enhance PLWD quality of life. Many factors, however, preclude caregivers' attendance in group-based programs and limit programs' scalability. To address the issue of access, the researchers have developed the Tele-Savvy program, an online version of SCP that brings groups of caregivers together in facilitator-led synchronous groups and provides substantive educational augmentation through asynchronous e-mail-delivered video lessons.

The first aim of this study is to develop a fully asynchronous online Savvy program that incorporates learning activities that promote both knowledge and skill acquisition and develop and enhance caregivers' felt-sense of caregiving mastery. Developing this education program will utilize input from clinicians, educators, Tele-Savvy facilitators, and caregiver advisors. The second study aim is to determine the feasibility, acceptability and preliminary efficacy of the created online program. This study will recruit 60 family caregivers to take part in a no-control trial of the program. Data will be gathered at baseline, immediately upon course completion and at 3 months post-baseline to assess caregiver distress measures (depression, strain, burden, anxiety), caregiver competence/ mastery, and care recipient quality of life.
PURPOSE: A system for digital scale designed to output diet information transmitted through the internet is provided to display and print the diet information transmitted through the internet. CONSTITUTION: A user's weight is measured(S702) and the user inputs the user input information through a keyboard, which is installed on a digital scale(S704). A server computer's communication interface receives the user's weight and input information from the digital scale. The server computer's user identifier identifies the user by determining whether the user ID from the transmitted user information is identical to the stored user ID(S706). If the user ID is not identified by the user identifier, the digital scale user registers one's user ID in the server computer(S708). The server computer's weight difference calculator calculates the difference between the transmitted weight and the weight stored in a DB(S710). The weight difference calculator calculates the necessary daily calory amount based on the daily calory consumption amount and the body fat level that are stored in the DB(S712). The server computer's diet information generator responds to the necessary daily calory consumption level and transmits the diet information through the internet(S714). The received diet information is displayed on an LCD screen or printed by a printer(S716).
Efficacy of repetitive transcranial magnetic stimulation (rTMS) in chronic tinnitus is moderate. So far single sessions and daily treatment of rTMS were rarely combined. Thus it is not clear if temporary reductions in tinnitus loudness as elicited by short single rTMS sessions can be transferred to daily rTMS treatment. Thus, the aim of the study is to investigate the efficacy and reliability of single sessions of rTMS in chronic tinnitus with respect to temporary reductions in tinnitus loudness accompanied with resting state electroencephalography measurements to investigate the neurophysiological correlates of tinnitus reductions. Two test sessions within one week will be done on the left and right temporoparietal junction using 1Hz, 10Hz, 20Hz and 0.1Hz as active control condition. In the next step patients are divided into three arms with the aim to investigate the efficacy of individualized rTMS. The three arms are 1) patients with temporary tinnitus reductions in test sessions: treatment with the best, most reliable, controlled and most tolerable protocol, 2) patients with temporary tinnitus reductions in test sessions: treatment with 1Hz left-sided rTMS, 3) patients with no temporary tinnitus reductions in test sessions: treatment with 1Hz left-sided rTMS. Treatment will be done for 10 days (Monday - Friday) using 2000 pulses with 110% resting motor threshold. Coil position will be tracked with neuronavigation to ensure stable coil Position over the course of the trial.
Participants randomized into the "Functional Medicine Health Coaching for Elimination Diet" arm will receive five remote health coaching sessions over 10 weeks in support of their progress through an elimination diet. All study arms will receive written elimination diet support materials.
The time limit of attempt selective cannulation by trainees is limited to 5 minutes. If the trainees failed to enter the targeted duct within 5 minutes, the senior endoscopist would take over the duodenoscope and continue the following procedure of cannulation.
PURPOSE: A biomarker for diagnosing essential hypertension is provided to develop a diagnostic kit and therapeutic agent. CONSTITUTION: A biomarker for diagnosing essential hypertension contains GTP-CH(Guanosine Triphosphate cyclohydrolase) and DHPR(Dihydropteridin reductase), and SR(Sepiapterin reductase). DHPR protein has an amino acid sequence of sequence number 1. An agent for diagnosing essential hypertension contains the biomarker or antibody which specifically binds to an immunogen fragment of the biomarker. The antibody is a monoclonal antibody. A kit for diagnosing essential hypertension contains the biomarker or the antibody as an active ingredient.